Abstract
Aim:Low-level laser therapy (LLLT) is a therapeutic photobiostimulation with properties in reducing swelling, inflammation, and promoting tissue healing. The objective of this pilot study was to evaluate LLLT in sterile pyogranulomatous pododermatitis in five dogs.Materials and Methods:In each dog, one lesion was designated as the control (treated with a 0.0584% hydrocortisone aceponate spray), and one or more other lesions were treated with a gallium aluminum arsenide-laser, daily for 5 days. Lesions were scored before treatment (D0), at the end (D4), 16 days after the last laser treatment (D20), and after 2 months (D65).Results:Comparing the treated lesion group with the control lesion group, the clinical score was similar at D0, whereas there was a statistically significant difference at D4 and D20; in the treated group over time, there was a statistically significant improvement between D0, D4, and D20. Lesion recurrence was absent in more than 50% of the treated lesions at D65. No adverse reactions were reported.Conclusion:Given the positive results of this first clinical study, it would be interesting to extend the study to confirm the validity of this type of therapy in sterile pyogranulomatous pododermatitis in the dog.
Highlights
Low-level laser therapy (LLLT) is a therapeutic modality of photobiostimulation that uses the emission of a coherent or non-coherent light source, or a combination of both [1]
Materials and Methods: In each dog, one lesion was designated as the control, and one or more other lesions were treated with a gallium aluminum arsenide-laser, daily for 5 days
Given the positive results of this first clinical study, it would be interesting to extend the study to confirm the validity of this type of therapy in sterile pyogranulomatous pododermatitis in the dog
Summary
Low-level laser therapy (LLLT) is a therapeutic modality of photobiostimulation that uses the emission of a coherent (laser) or non-coherent (filtered lamps or light emitting diode [LED]) light source, or a combination of both [1]. It uses red and near-infrared (NIR) light with wavelengths between 300 and 10,600 nm. The basic biological mechanisms responsible for the effects of LLLT are not yet fully understood [1]. The effects are thought to be mediated by absorption of red and NIR light by mitochondrial chromophores, in particular, cytochrome C oxidase [3]. A cascade of events occur, with upregulation of oxidative phosphorylation and increased production of adenosine triphosphate, leading to activation of fibroblasts, keratinocytes, and endothelial cells, producing a reduction of pain, edema, and inflammation [4]
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call